A Phase I, Randomized, Open-label, 3 or 4-period, 7-treatment, Single-dose, Two Cohort, Crossover Study to Assess the Relative Bioavailability of Laroprovstat/Rosuvastatin Fixed Combination Drug Products to the Single Therapy Products in Healthy Adults
Latest Information Update: 14 Jan 2026
At a glance
- Drugs Laroprovstat/Rosuvastatin (Primary) ; Laroprovstat; Rosuvastatin
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 14 Jan 2026 New trial record